Pure Global
NCT03553537

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Southwest Hospital, China·Phase 3·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Decitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Southwest Hospital, China
Timeline & enrollment
Phase
Phase 3
Start date
Jun 01, 2018
End date
Jul 01, 2021
Enrollment
100 participants
Primary outcome

Progression Free Survival

Summary

Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP
 (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma
 (PTCL).

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03553537
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03553537 through Pure Global AI's free database. This Phase 3 trial is sponsored by Southwest Hospital, China and is currently status unknown. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.